公开(公告)号：US20210332045A1

公开(公告)日：2021-10-28

申请号：US17367171

申请日：2021-07-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Toshio Tanaka ,  Yasuyoshi Arikawa ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US11584737B2

公开(公告)日：2023-02-21

申请号：US17042394

申请日：2019-03-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji Ono ,  Masahiro Ito ,  Toshio Tanaka ,  Moriteru Asano ,  Takaharu Hirayama ,  Jun Fujimoto ,  Nobuki Sakauchi ,  Yasuhiro Hirata ,  Akinori Toita ,  Nao Morishita ,  Hironori Kokubo ,  Yasuhiro Imaeda ,  Hironobu Maezaki ,  Douglas Robert Cary ,  Ryo Mizojiri ,  Nobuo Cho ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Yasuyoshi Arikawa

IPC: C07D401/14 ,  C07D403/14 ,  A61P35/00 ,  C07D213/84 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D471/10 ,  C07D487/10 ,  C07D495/10

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US11230545B2

公开(公告)日：2022-01-25

申请号：US17367171

申请日：2021-07-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Toshio Tanaka ,  Yasuyoshi Arikawa ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US11952344B2

公开(公告)日：2024-04-09

申请号：US17754118

申请日：2020-09-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya Oguro ,  Makoto Kamata ,  Shuhei Ikeda ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Shigemitsu Matsumoto ,  Hirotaka Kamitani ,  Takaharu Hirayama ,  Toshio Tanaka ,  Hiroshi Banno ,  Nobuyuki Takakura ,  Jinichi Yonemori ,  Takuya Fujimoto

IPC: C07D213/61 ,  A61K31/444 ,  A61K31/495 ,  A61P25/00 ,  A61P29/00 ,  C07D211/04 ,  C07D213/65 ,  C07D213/68 ,  C07D221/04 ,  C07D237/08 ,  C07D239/26 ,  C07D239/34 ,  C07D333/38 ,  C07D401/12 ,  C07D405/02

CPC classification number: C07D211/04 ,  C07D237/08 ,  C07D239/26 ,  C07D405/02

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.